A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

NCT06381843 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV-2 Infection

Interventions

BIOLOGICAL: Recombinant COVID-19 Vaccine (Sf9 Cell)
BIOLOGICAL: COVID-19 Vaccine (Vero Cell), Inactivated

Sponsor

WestVac Biopharma Co., Ltd.

Collaborators

[object Object]